The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced (muscle ...

Bladder cancer patients treated with a breakthrough drug are a third less likely to see their disease return and have higher ...

An English-Greek man had the distinction of being the designer of one of the two most emblematic cars in the world, the Mini Cooper.